Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of intradiscal STA363 for chronic discogenic low back pain
NL-OMON49183Phase 2Active, not recruiting
- Sponsor
- Stayble Therapeutics
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lactic acid in discogenic back pain and degenerative disc disease (DDD) (3 arms), sponsored by Stayble Therapeutics. Primary endpoint: Change from baseline in mean pain intensity at Month 6. Started Aug 2020; status: active, not recruiting.
02
Drugs
lactic acid
03
Conditions
discogenic back paindegenerative disc disease (DDD)
Beyond the preview
Go deeper on NL-OMON49183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49183.